Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
$11.65
+2.5%
$9.15
$3.92
$19.15
$102.45M0.0878,831 shs31,653 shs
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$13.92
+8.8%
$10.14
$6.62
$13.94
$1.19B1.21.10 million shs1.12 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$99.24
-2.9%
$70.25
$23.30
$105.47
$6.37B2.112.20 million shs1.52 million shs
Vericel Corporation stock logo
VCEL
Vericel
$46.98
+4.1%
$36.96
$28.95
$47.06
$2.31B1.07708,223 shs640,678 shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
+2.46%+13.99%+17.68%+133.47%+41.21%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
+8.75%+20.73%+50.65%+51.63%+101.16%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-2.94%+2.68%+41.47%+97.65%+163.38%
Vericel Corporation stock logo
VCEL
Vericel
+4.05%+9.51%+36.37%+37.61%+13.31%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
$11.65
+2.5%
$9.15
$3.92
$19.15
$102.45M0.0878,831 shs31,653 shs
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$13.92
+8.8%
$10.14
$6.62
$13.94
$1.19B1.21.10 million shs1.12 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$99.24
-2.9%
$70.25
$23.30
$105.47
$6.37B2.112.20 million shs1.52 million shs
Vericel Corporation stock logo
VCEL
Vericel
$46.98
+4.1%
$36.96
$28.95
$47.06
$2.31B1.07708,223 shs640,678 shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
+2.46%+13.99%+17.68%+133.47%+41.21%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
+8.75%+20.73%+50.65%+51.63%+101.16%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-2.94%+2.68%+41.47%+97.65%+163.38%
Vericel Corporation stock logo
VCEL
Vericel
+4.05%+9.51%+36.37%+37.61%+13.31%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
2.00
Hold$9.50-18.45% Downside
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
2.75
Moderate Buy$25.8385.58% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.80
Moderate Buy$79.30-20.09% Downside
Vericel Corporation stock logo
VCEL
Vericel
2.43
Hold$52.5011.75% Upside

Current Analyst Ratings Breakdown

Latest MGTX, VCEL, TWST, and ATRA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/29/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetBuy$60.00 ➝ $107.00
6/24/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Reiterated RatingSell (D-)
6/24/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetOverweight$65.00 ➝ $95.00
6/16/2026
Vericel Corporation stock logo
VCEL
Vericel
UpgradeSell (D)Sell (D+)
6/15/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetBuy$68.00 ➝ $89.00
6/15/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Initiated CoverageBuy$90.00
6/15/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Set Price Target$89.00
6/15/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetBuy$68.00 ➝ $89.00
6/15/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Initiated CoverageBuy$90.00
6/11/2026
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
DowngradeSell (D)Sell (E+)
6/11/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Initiated CoverageOverweight$85.00
(Data available from 7/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
$120.77M0.87$4.98 per share2.34($5.34) per share-2.18
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$81.39M15.84N/AN/A($0.07) per share-198.86
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$376.57M16.41N/AN/A$7.84 per share12.66
Vericel Corporation stock logo
VCEL
Vericel
$276.26M8.68$0.58 per share81.28$7.01 per share6.70
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
$32.69M-$0.67N/A8.32N/A-40.91%-79.12%-35.29%8/10/2026 (Estimated)
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$114.20M-$1.48N/AN/AN/A-151.12%N/A-54.96%8/13/2026 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$77.67M-$1.33N/AN/AN/A-19.85%-26.73%-19.15%8/3/2026 (Estimated)
Vericel Corporation stock logo
VCEL
Vericel
$16.52M$0.42111.8655.93N/A7.35%6.41%4.61%7/30/2026 (Estimated)

Latest MGTX, VCEL, TWST, and ATRA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2026Q2 2026
Vericel Corporation stock logo
VCEL
Vericel
-$0.04N/AN/AN/A$72.70 millionN/A
5/14/2026Q1 2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$0.6060-$0.57+$0.0360-$0.57$17.00 million$0.29 million
5/12/2026Q1 2026
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
-$0.3295-$0.29+$0.0395-$0.29$2.90 million$0.52 million
5/7/2026Q1 2026
Vericel Corporation stock logo
VCEL
Vericel
-$0.15-$0.12+$0.03-$0.12$63.68 million$68.43 million
5/4/2026Q2 2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.49-$0.71-$0.22-$0.71$107.64 million$110.72 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
N/AN/AN/AN/AN/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
Vericel Corporation stock logo
VCEL
Vericel
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
N/A
2.16
2.16
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
N/A
0.55
0.55
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
2.70
2.42
Vericel Corporation stock logo
VCEL
Vericel
N/A
5.18
4.79

Institutional Ownership

CompanyInstitutional Ownership
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
70.90%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
67.48%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A
Vericel Corporation stock logo
VCEL
Vericel
N/A

Insider Ownership

CompanyInsider Ownership
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
41.20%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
7.40%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.08%
Vericel Corporation stock logo
VCEL
Vericel
7.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
3309.01 million5.30 millionNo Data
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
30092.61 million85.76 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99062.27 million60.35 millionOptionable
Vericel Corporation stock logo
VCEL
Vericel
30051.07 million47.19 millionOptionable

Recent News About These Companies

Sean Flynn Sells 15,000 Shares of Vericel (NASDAQ:VCEL) Stock
Vericel (NASDAQ:VCEL) Insider Sells 2,732 Shares of Stock
Vericel Corporation
Vericel (VCEL) Q1 2026 Earnings Transcript
Vericel Q1 2026 earnings preview

New MarketBeat Followers Over Time

Media Sentiment Over Time

Atara Biotherapeutics stock logo

Atara Biotherapeutics NASDAQ:ATRA

$11.65 +0.28 (+2.46%)
As of 07/2/2026 04:00 PM Eastern

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

MeiraGTx stock logo

MeiraGTx NASDAQ:MGTX

$13.92 +1.12 (+8.75%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$13.70 -0.22 (-1.58%)
As of 07/2/2026 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$99.24 -3.01 (-2.94%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$97.56 -1.68 (-1.70%)
As of 07/2/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Vericel stock logo

Vericel NASDAQ:VCEL

$46.98 +1.83 (+4.05%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$46.98 0.00 (-0.01%)
As of 07/2/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.